Kajian Sistematik: Efek Gen Multi Drug Resistance-1 pada Farmakokinetik Klopidogrel

  • Rasmaya Niruri Universitas Sebelas Maret
  • Rini Noviyani universitas udayana
  • indah Mei Rahajeng universitas udayana
Keywords: MDR-1, 3435 variant, Clopidogrel pharmacokinetic

Abstract

Multi Drug Resistance-1 (MDR-1) gene polymorphisms encoding for P-glycoprotein can affect clopidogrel intestinal absorption. This systematic review aim to identify the impact of MDR-1 gene 3435 variants on clopidogrel pharmacokinetics. Literature review were retrieved from MEDLINE, Science Direct, Scopus, Clinical Key, ProQuest and Google Scholar databases. The articles are critically reviewed and analyzed to answer this systematic review’s aim. The result showed that, in patients with cardiovascular disease, the peak plasma concentration (Cmax) and the total area under the plasma concentration–time curve (AUC) of clopidogrel and its active metabolites were lower in 3435TT compared to 3435CC. Nevertheless, the variants of MDR-1 gene were not significantly correlated to the plasma concentration in healthy subjects. Clopidogrel pharmacokinetic profile varied widely between MDR-1 3435 variants and subjects.

Author Biographies

Rini Noviyani, universitas udayana
Program Studi Farmasi FMIPA
indah Mei Rahajeng, universitas udayana
Fakultas kedokteran

References

Brambilia AJL, Tapia. MDR1 (ABCB1) polymorphisms: functional effects and clinical implications. Revista de Investigación Clínica. 2013 Sept-Oct;65(5):445-54

Su J, Xu J, Li X, Zhang H, Hu J, Fang R. et al. ABCB1 C3435T polymorphism and response to clopidogrel treatment in coronary artery disease (CAD) patients: a meta-analysis. Plos One. 2012 Oct;7(10):1-14

Calderón-Cruz B, Rodríguez-Galván K, Manzo-Francisco LA, Vargas-Alarcón G, Fragoso JM, Peña-Duque MA, et al. C3435T polymorphism of the ABCB1 gene is associated with poor clopidogrel responsiveness in a Mexican population undergoing percutaneous coronary intervention. Thrombosis Research. 2015 Nov;136(5):894-8

Simon T, Verstuyft C, Mary-Krause M, Quteineh L, Drouet E, Meneveau N. et al. Genetic determinants of response toclopidogrel and cardiovascular events. New England Journal of Medicine. 2009 Jan;360(4):363-75

National Heart Lung and Blood Institute. Quality assessment tool for observational cohort and cross-sectional studies. USA: US Department of Health & Human Services; 2014.

Kim HS, Cho DY, Park BM, Bae SK, Yoon YJ, Minkyung O, et al. The Effect of CYP2C19 genotype on the timecourse of platelet aggregation inhibition afterclopidogrel administration. The Journal of Clinical Pharmacology. 2013;54(8):850–7.

Frelinger AL 3rd, Bhatt D, Lee RD, Mulford DJ, Wu J, Nudurupati S, Nigam A, et al. A randomized, 2-period, crossover design study toassess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics ofclopidogrel in healthy volunteers. Journal of the American College of Cardiology. 2012;59(14):1304–11

Wang XQ, Shen CL, Wang BN, Huang XH, Hu ZL, Li J. Genetic polymorphisms of CYP2C192 and ABCB1 C3435T affect the pharmacokinetic and pharmacodynamic responses to clopidogrel in 401 patients with acute coronarysyndrome. Gene. 2012 Mar;558(2):200-7.

Taubert D, Von Beckerath N, Grimberg G, Lazar A, Jung N, Goeser T, et al. Impact of P-glycoprotein on clopidogrel absorption. Clinical Pharmacology and Therapeutics. 2006 Nov;80(5):486-501

Karazniewicz-Łada M, Danielak D, Rubis B, Burchardt P, Komosa A, Lesiak M, et al. Impact of common ABCB1 polymorphism on pharmacokinetics and pharmacodynamics of clopidogrel and its metabolites. Journal of Clinical Pharmacy and Therapeutics. 2014 Nov;40(2):226-31

Danese E, Fava C, Beltrame F, Tavella D, Calabria S, Benati M, et al. Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry. Journal of Thrombosis and Haemostasis. 2016 Feb; 14(2): 282–93.

Danielak D, Karaźniewicz-Łada M, Komosa A, Burchardt P, Lesiak M, Kruszyna L. et al. Influence of genetic co-factors on the population pharmacokinetic model for clopidogrel and its active thiol metabolite. European Journal of Clinical Pharmacology. 2017;73(12):1623–32

Braun OÖ, Angiolillo DJ, Ferreiro JL, Jakubowski JA,Winters KJ, Effron M, et al. Enhanced active metabolite generation and platelet inhibition with prasugrel compared to clopidogrel regardless of genotype in thienopyridine metabolic pathways. Thrombosis and Haemostasis. 2013 Dec; 110(6): 1223–31

Wessler JD, Grip LT, Mendell J, Giugliano RP. The P-glycoprotein transport system and cardiovascular drugs. Journal of the American College of Cardiology. 2013 Jun;61(25):2495–502

Yano K, Tomono T, Ogihara T. Advances in studies of P-glycoprotein and Its expression regulators. Biological & Pharmaceutical Bulletin. 2018;41(1):11–9.

Auzmendi J, Merelli A, Girardi E, Orozco-Suarez S, Rocha L, Lazarowski A. Progressive heart P-glycoprotein (P-gp) overexpression after experimental repetitive seizures (ERS) associated with fatal status epilepticus (FSE) Is it related with SUDEP?. Molecular & Cellular Epilepsy. 2014 Feb;3:1-9

Ho GT, Moodie FM, Satsangi J. Multidrug resistance 1 gene (P-glycoprotein 170): animportant determinant in gastro intestinal disease?. Gut. 2003 May;52(5):759–66.

Published
2019-05-17
How to Cite
1.
Niruri R, Noviyani R, Rahajeng indah. Kajian Sistematik: Efek Gen Multi Drug Resistance-1 pada Farmakokinetik Klopidogrel. jki [Internet]. 17May2019 [cited 26May2022];9(1):65-2. Available from: https://ejournal2.litbang.kemkes.go.id/index.php/jki/article/view/584
Section
Articles